Etanercept biosimilar (Hanwha Chemical) |
依那西普生物类似药(Hanwha Chemical) |
HD-203; MK-8953 |
批准上市 |
Hanwha Chemical |
|
|
|
|
|
强直性脊柱炎, 斑块状银屑病, 银屑病关节炎, 类风湿性关节炎 |
详情
|
Etanercept-szzs |
依那西普生物类似药 (Sandoz) |
GP-2015 |
批准上市 |
山德士 |
ERELZI |
fda |
幼年特发性关节炎, 斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎 |
SANDOZ |
2016-08-30 |
幼年特发性关节炎, 脊柱关节炎, 斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎 |
详情
|
Infliximab |
英夫利西单抗 |
TA-650 |
批准上市 |
杨森, 默沙东, 田边三菱制药 |
REMICADE |
fda |
溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 克罗恩氏病 |
CENTOCOR INC |
1998-08-24 |
儿童溃疡性结肠炎, 寻常型银屑病, 克罗恩氏病, 黏膜皮肤淋巴结综合征, 红皮病型银屑病, 强直性脊柱炎, 眼色素层炎, 脓疱型银屑病, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 贝赫切特综合征, 儿童节段性回肠炎 |
详情
|
Etanercept biosimilar (Nanogen Biopharmaceutical) |
依那西普生物类似药(Nanogen Biopharmaceutical) |
|
批准上市 |
Nanogen Biopharmaceutical Co |
|
|
|
|
|
银屑病, 类风湿性关节炎 |
详情
|
Adalimumab biosimilar (AXXO) |
阿达木单抗生物类似药 (AXXO) |
|
批准上市 |
AXXO |
|
|
|
|
|
银屑病关节炎, 类风湿性关节炎 |
|
Etanercept biosimilar (AryoGen Biopharma) |
依那西普生物类似药 (AryoGen Biopharma) |
|
批准上市 |
AryoGen Biopharma |
|
|
|
|
|
斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
详情
|
Certolizumab pegol |
|
CZP; CDP-870; PHA-738144,CDP870,PHA738144 |
批准上市 |
优时比 |
CIMZIA |
fda |
银屑病关节炎, 类风湿性关节炎, 克罗恩氏病 |
UCB INC |
2008-04-22 |
斑块状银屑病, 脊柱关节炎, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎, 克罗恩氏病 |
详情
|
Etanercept biosimilar (PROBIOMED) |
依那西普生物类似药 (PROBIOMED) |
|
批准上市 |
Probiomed |
|
|
|
|
|
类风湿性关节炎 |
|
Etanercept |
依那西普 |
TNR-001 |
批准上市 |
安进, 辉瑞, 武田, 勃林格殷格翰 |
ENBREL |
fda |
儿童斑块状银屑病, 斑块状银屑病, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
IMMUNEX |
1998-11-02 |
幼年特发性关节炎, 儿童斑块状银屑病, 脊柱关节炎, 斑块状银屑病, 强直性脊柱炎, 银屑病, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Zydus Cadila) |
阿达木单抗生物类似药 (Zydus Cadila) |
|
批准上市 |
Zydus cadila |
|
|
|
|
|
强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
|
Etanercept biosimilar (Shanghai CP Guojian Pharmaceutical) |
依那西普生物类似药 (Shanghai CP Guojian Pharmaceutical) |
|
批准上市 |
三生国健药业(上海), 西普拉有限公司 |
|
cfda |
强直性脊柱炎, 类风湿性关节炎, 斑块状银屑病 |
|
2015-01-27 |
斑块状银屑病, 强直性脊柱炎, 类风湿性关节炎 |
详情
|
Etanercept biosimilar (Samsung Bioepis) |
依那西普生物类似药(三星 Bioepis) |
SB-4 |
批准上市 |
三星Bioepis |
etanercept |
ema |
Rheumatoid arthritis
Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying |
Samsung Bioepis NL B.V. |
2016-01-13 |
幼年特发性关节炎, 脊柱关节炎, 斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Fujifilm Kyowa Kirin Biologics/Mylan) |
阿达木单抗生物类似药(富士-协和麒麟生物制剂公司/迈兰制药) |
FKB-327 |
批准上市 |
Fujifilm Kyowa Kirin Biologics, 迈兰制药 |
adalimumab |
ema |
|
Mylan S.A.S. |
2018-09-16 |
斑块状银屑病, 眼色素层炎, 强直性脊柱炎, 溃疡性结肠炎, 银屑病, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎, 幼年型类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Biocad) |
阿达木单抗生物类似药 (Biocad) |
BCD-057 |
批准上市 |
Biocad |
|
|
|
|
|
斑块状银屑病 |
详情
|
Adalimumab biosimilar (Sandoz) |
阿达木单抗生物类似药(Sandoz) |
GP-2017 |
批准上市 |
山德士 |
adalimumab |
ema |
Rheumatoid arthritis Hyrimoz in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response t
|
Sandoz GmbH |
2018-07-26 |
幼年特发性关节炎, 眼色素层炎, 脊柱关节炎, 儿童斑块状银屑病, 溃疡性结肠炎, 银屑病, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病 |
详情
|
Pomalidomide |
泊马度胺 |
CC-4047; CDC-394; IMID-4047; IMiD-1 |
批准上市 |
新基 |
POMALYST |
fda |
多发性骨髓瘤 |
CELGENE |
2013-02-08 |
多发性骨髓瘤 |
详情
|
Infliximab biosimilar (Bionovis/The Instituto Vital Brazil) |
英夫利西单抗生物类似药(Bionovis/The Instituto Vital Brazil) |
|
批准上市 |
Bionovis, The Instituto Vital Brazil |
|
|
|
|
|
斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 克罗恩氏病 |
详情
|
Etanercept biosimilar (Intas Biopharmaceuticals) |
依那西普生物类似药 (Intas Biopharmaceuticals) |
|
批准上市 |
Intas Biopharmaceuticals |
|
|
|
|
|
斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
|
Etanercept biosimilar (Mochida) |
依那西普生物类似药 (Mochida) |
LBEC-0101 |
批准上市 |
持田制药, Ayumi |
|
日本 |
类风湿性关节炎, 幼年特发性关节炎 |
持田制药 |
2018-01-19 00:00:00.0 |
幼年特发性关节炎, 类风湿性关节炎 |
|
Adalimumab-adbm |
|
BI-695501 |
批准上市 |
勃林格殷格翰 |
CYLTEZO |
fda |
幼年特发性关节炎, 强直性脊柱炎, 斑块状银屑病, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 克罗恩氏病 |
BOEHRINGER INGELHEIM |
2017-08-25 |
幼年特发性关节炎, 眼色素层炎, 斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎 |
详情
|
Golimumab |
戈利木单抗 |
CNTO-148; rTNV148B,CNTO148 |
批准上市 |
杨森, 默沙东, 田边三菱制药 |
SIMPONI |
fda |
溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎 |
CENTOCOR ORTHO BIOTECH INC |
2009-04-24 |
幼年特发性关节炎, 强直性脊柱炎, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎 |
详情
|
Infliximab biosimilar (Amgen) |
英夫利昔单抗生物类似药(安进) |
ABP-710 |
批准上市 |
安进 |
AVSOLA |
fda |
|
AMGEN INC |
2019-12-06 |
强直性脊柱炎, 儿童溃疡性结肠炎, 溃疡性结肠炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎, 儿童节段性回肠炎 |
详情
|
Infliximab (ABDA) |
|
SB-2 |
批准上市 |
三星Bioepis, 默沙东 |
infliximab |
ema |
Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: |
Samsung Bioepis NL B.V. |
2016-05-26 |
斑块状银屑病, 强直性脊柱炎, 银屑病, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 克罗恩氏病, 儿童节段性回肠炎 |
详情
|
Infliximab-qbtx |
|
PF-06438179; PF-6438179; GP-1111,PF06438179; PF6438179 |
批准上市 |
辉瑞, 山德士 |
IXIFI |
fda |
|
PFIZER INC |
2017-12-13 |
红皮病型银屑病, 强直性脊柱炎, 斑块状银屑病, 脓疱型银屑病, 溃疡性结肠炎, 银屑病关节炎, 寻常型银屑病, 克罗恩氏病, 类风湿性关节炎, 儿童节段性回肠炎 |
详情
|
Pentoxifylline |
己酮可可碱 |
BL-191; EHT-0201; EHT-201 |
批准上市 |
Us Pharm Holdings |
TRENTAL |
fda |
|
US PHARM HOLDINGS |
1984-08-30 |
外周血管疾病 |
详情
|
Infliximab (dyyb) |
|
CT-P13,CTP13 |
批准上市 |
Celltrion, Hospira, 日本化药株式会社 |
infliximab |
ema |
Rheumatoid arthritis Inflectra, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: |
Pfizer Europe MA EEIG |
2013-09-09 |
红皮病型银屑病, 斑块状银屑病, 强直性脊柱炎, 脓疱型银屑病, 银屑病, 溃疡性结肠炎, 银屑病关节炎, 寻常型银屑病, 类风湿性关节炎, 克罗恩氏病, 儿童节段性回肠炎 |
详情
|
Adalimumab biosimilar (Fresenius Kabi) |
阿达木单抗生物类似药 (Fresenius Kabi) |
MSB-11022 |
批准上市 |
默克雪兰诺, Fresenius Kabi |
adalimumab |
ema |
Rheumatoid arthritis Idacio in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumat
|
Fresenius Kabi Deutschland GmbH |
2019-04-02 |
眼色素层炎, 斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病, 幼年型类风湿性关节炎 |
详情
|
Etanercept biosimilar (Hisun-Pfizer Pharmaceuticals) |
依那西普生物类似药 (Hisun-Pfizer Pharmaceuticals) |
|
批准上市 |
Hisun-Pfizer |
|
|
|
|
|
斑块状银屑病, 强直性脊柱炎, 银屑病关节炎, 类风湿性关节炎 |
详情
|
PG-201 |
|
PG-201,PG 201 |
批准上市 |
ViroMed, PMG Pharm |
|
|
|
|
|
骨关节炎 |
详情
|
Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) |
英夫利西单抗生物类似药 (Nichiiko Pharmaceutical/Aprogen) |
GS-071; NI-071 |
批准上市 |
Nichi-Iko Pharmaceutical, Aprogen, Zeria, Ayumi |
Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) |
日本 |
类风湿性关节炎, 寻常型银屑病, 银屑病关节炎, 脓疱型银屑病, 克罗恩氏病, 溃疡性结肠炎 |
Nichi-Iko Pharmaceutical,Zeria |
2017-09-27 00:00:00.0 |
脓疱型银屑病, 溃疡性结肠炎, 银屑病关节炎, 寻常型银屑病, 克罗恩氏病, 类风湿性关节炎 |
详情
|
Luminol sodium |
|
MP-1032,MP1032 |
批准上市 |
Metrio, Selvim |
|
|
|
|
|
银屑病, 免疫性疾病 |
详情
|
Adalimumab-afzb |
阿达木单抗生物类似药(辉瑞) |
PF-06410293 |
批准上市 |
辉瑞 |
ABRILADA |
fda |
|
PFIZER INC |
2019-11-15 |
幼年特发性关节炎, 斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Amgen) |
|
ABP-501 |
批准上市 |
安进, 第一三共 |
AMJEVITA |
fda |
幼年特发性关节炎, 斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎 |
AMGEN INC |
2016-09-23 |
幼年特发性关节炎, 眼色素层炎, 强直性脊柱炎, 斑块状银屑病, 溃疡性结肠炎, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Samsung Bioepis) |
阿达木单抗生物类似药(三星Bioepis) |
SB-5 |
批准上市 |
三星Bioepis |
adalimumab |
ema |
Rheumatoid arthritis Imraldi in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response t
|
Samsung Bioepis NL B.V. |
2017-08-24 |
儿童斑块状银屑病, 脊柱关节炎, 化脓性汗腺炎, 克罗恩氏病, 幼年特发性关节炎, 眼色素层炎, 强直性脊柱炎, 银屑病, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 儿童节段性回肠炎 |
详情
|
Lenalidomide |
来那度胺 |
CDC-501; CC-5013; CDC-5013; ENMD-0997; IMID-5013; IMiD-3 |
批准上市 |
新基, 百济神州 |
REVLIMID |
fda |
骨髓增生异常综合征, 套细胞淋巴瘤, 多发性骨髓瘤 |
CELGENE |
2005-12-27 |
骨髓增生异常综合征, 套细胞淋巴瘤, 多发性骨髓瘤, 外周T细胞淋巴瘤 |
详情
|
Adalimumab |
阿达木单抗 |
D2E7; LU-200134; ABT-D2E7 |
批准上市 |
艾伯维 |
HUMIRA |
fda |
幼年特发性关节炎, 眼色素层炎, 斑块状银屑病, 强直性脊柱炎, 化脓性汗腺炎, 银屑病关节炎, 克罗恩氏病, 类风湿性关节炎, 儿童节段性回肠炎 |
ABBVIE INC |
2002-12-31 |
脊柱关节炎, 化脓性汗腺炎, 克罗恩氏病, 幼年特发性关节炎, 强直性脊柱炎, 斑块状银屑病, 眼色素层炎, 脓疱型银屑病, 银屑病, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎, 儿童节段性回肠炎 |
详情
|
Infliximab biosimilar (Reliance Life Sciences) |
英夫利西单抗生物类似药 (Reliance Life Sciences) |
BOW-015; R-TPR-015 |
批准上市 |
EPIRUS Biopharmaceuticals, 太阳制药 |
|
|
|
|
|
类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Bio-Thera Solutions) |
阿达木单抗生物类似药(百奥泰生物) |
BAT-1406 |
批准上市 |
百奥泰生物科技 |
Adalimumab Injection |
cfda |
强直性脊柱炎, 类风湿性关节炎, 银屑病 |
|
2019-11-04 |
强直性脊柱炎, 银屑病, 类风湿性关节炎 |
详情
|
Infliximab biosimilar (AXXO) |
英夫利西单抗生物类似药 (AXXO) |
|
批准上市 |
AXXO |
|
|
|
|
|
自身免疫疾病, 克罗恩氏病 |
|
Adalimumab biosimilar (Hisun Pharma) |
阿达木单抗(海正药业) |
HS-016,HS016 |
批准上市 |
浙江海正药业 |
Adalimumab Solution for Injection |
cfda |
强直性脊柱炎 |
|
2019-12-06 |
斑块状银屑病, 强直性脊柱炎, 类风湿性关节炎 |
|
Etanercept biosimilar (Amega Biotech) |
依那西普生物类似药 (Amega Biotech) |
|
批准上市 |
Amega Biotech |
|
|
|
|
|
类风湿性关节炎 |
详情
|
Etanercept biosimilar (Mylan) |
依那西普生物类似药 (Mylan) |
YLB-113 |
批准上市 |
Lupin, 迈兰制药, YL Biologics |
etanercept |
ema |
Rheumatoid arthritis Nepexto in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumati |
Mylan IRE Healthcare Limited |
2020-05-20 |
斑块状银屑病, 脊柱关节炎, 银屑病关节炎, 类风湿性关节炎, 幼年型类风湿性关节炎 |
详情
|
Etanercept biosimilar (Mycenax Biotech/TSH Biopharm) |
依那西普生物类似药 (Mycenax Biotech/TSH Biopharm) |
E-11; ENIA-11,E11; ENIA11 |
批准上市 |
永昕生物医药, TSH Biopharm |
|
|
|
|
|
类风湿性关节炎 |
详情
|
Adalimumab biosimilar (Reliance Life Sciences) |
阿达木单抗生物类似药(Reliance Life Sciences) |
R-TPR-021 |
批准上市 |
Reliance Life Sciences, Torrent Pharmaceuticals |
|
|
|
|
|
斑块状银屑病, 强直性脊柱炎, 溃疡性结肠炎, 银屑病关节炎, 类风湿性关节炎 |
|
Thalidomide |
沙利度胺 |
NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 |
批准上市 |
新基 |
THALOMID |
fda |
麻风结节性红斑, 多发性骨髓瘤 |
CELGENE |
1998-07-16 |
麻风结节性红斑, 多发性骨髓瘤 |
详情
|
Anti-tumour necrosis factor-alpha antibody |
|
|
批准上市 |
Materia Medica Holding Research and Production Company |
|
|
|
|
|
骨关节炎, 类风湿性关节炎 |
|